The Comprehensive Myeloid Panel is a next-generation sequencing (NGS) assay designed to assist oncologists with the diagnosis and prognostication of myeloid malignancies. Covering 66 clinically relevant genes, the panel detects both somatic mutations and gene fusions through integrated DNA and RNA analysis. This enables a complete and efficient molecular workup, supporting precise classification, risk stratification, and the identification of actionable targets in a single test across a broad spectrum of myeloid disorders.
Individuals with suspected/confirmed myeloid malignancies, including:
